Vasu Pharma Distributors Hyd Profile
Key Indicators
- Authorised Capital ₹ 1.25 Cr
- Paid Up Capital ₹ 1.00 Cr
- Company Age 7 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 18.00 Cr
- Revenue Growth -1.09%
- Profit Growth -408.40%
- Ebitda -23.80%
- Net Worth -4.25%
- Total Assets -44.47%
About Vasu Pharma Distributors Hyd
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909TG2017PTC121037
- Company No.
121037
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Dec 2017
- Date of AGM
08 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Vasu Pharma Distributors Hyd?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramesh Bejgam  | Managing Director | 07-Dec-2017 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Akshay Bejgam | Director | 02-Apr-2018 | Current |
| Narasaiah Arigela | Nominee Director | 26-Aug-2020 | Current |
Financial Performance of Vasu Pharma Distributors Hyd.
Vasu Pharma Distributors Hyd Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 1.09% decrease. The company also saw a substantial fall in profitability, with a 408.4% decrease in profit. The company's net worth dipped by a decrease of 4.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vasu Pharma Distributors Hyd?
In 2023, Vasu Pharma Distributors Hyd had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Medchem International India Private LimitedRamesh Bejgam is a mutual person
Indian Hospitex Private LimitedNarasaiah Arigela is a mutual person
Vasu Organics Private LimitedRamesh Bejgam and Akshay Bejgam are mutual person
Vasu Pharma Drugs Private LimitedRamesh Bejgam and Akshay Bejgam are mutual person
- Vasu Agencies Drugs Private Limited
Ramesh Bejgam is a mutual person
- New Viswabharathy Drug Lines Private Limited
Narasaiah Arigela is a mutual person
Charges (Loans)
₹0
₹18.00 Cr
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 18.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 14 Mar 2018 | Hdfc Bank Limited | ₹18.00 Cr | Satisfied |
How Many Employees Work at Vasu Pharma Distributors Hyd?
Vasu Pharma Distributors Hyd has a workforce of 63 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vasu Pharma Distributors Hyd, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vasu Pharma Distributors Hyd's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
